ALZHEON, INC.

BiotechnologyBiotechnologyAlzheimer's

📍 Framingham, MA, United States

StreetZero Signal 73

Be the first to signal interest

About ALZHEON, INC.

ALZHEON, INC. is a clinical-stage biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative disorders. The company is headquartered in Framingham, Massachusetts and works on oral therapies targeting amyloid pathology. Its pipeline includes candidates such as ALZ-801, an oral prodrug designed for improved tolerability.

LATEST FUNDINGPrivate Placement

$78.8M

Announced 2026-09-10

TOTAL RAISED$78,797,184

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for ALZHEON, INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED—

HQFramingham, MA, United States

Industry

Biotechnology

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Raised $78.8 million via private placement
Headquartered in Framingham, MA
Focuses on Alzheimer's disease therapeutics

Ask StreetZero about ALZHEON, INC.

Put our AI to work on this deal.

What is ALZHEON, INC.'s value proposition?Who are ALZHEON, INC.'s competitors?Why does this raise matter?Summarize ALZHEON, INC. for an investor.

Similar companies

Other Biotechnology deals, ranked by Signal.

LISATA THERAPEUTICS, INC.

$351.9M

Virtual Incision Corp

$35.1M

Rakuten Medical, Inc.

$9.0M

Altay Therapeutics, Inc.

$15.7M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.